Identification of enzymes involved in Phase I metabolism of ciclesonide by human liver microsomes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 4, 2005, Pages 275-286

  Peet, C F ^a,c   Enos, T ^a   Nave, R ^b   Zech, K ^b   Hall, M ^a  

^a HUNTINGDON LIFE SCIENCES   (United Kingdom)

^b ALTANA PHARMA AG   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

16 hydroxyprednisolone; Ciclesonide; CYP3A; Des isobutyryl ciclesonide (des CIC); Esterase

Indexed keywords

CICLESONIDE; CORTICOSTEROID; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 4A; CYTOCHROME P450 4A11; DIETHYLDITHIOCARBAMIC ACID; PREDNISOLONE; PROADIFEN; QUINIDINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; ASTHMA; CATALYSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; METABOLITE; MICROSOME MEMBRANE; PHASE 1 CLINICAL TRIAL; REGRESSION ANALYSIS;

EID: 30744464352     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190632     Document Type: Article

References (22)

1. Bertz R.J., Granneman G.R. (1997): Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 32, 210-258.
2. Lin J.H., Lu A.Y.H. (1998): Inhibition and induction of cytochrome P450 and clinical implications. Clin. Pharmacokinet., 35, 361-390.
3. Yao C., Levy R.H. (2002): Inhibition-based metabolic drug-drug interactions: Predictions from in vitro data. J. Pharm. Sci., 91, 1923-1935.
4. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. (1996): P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
5. Tucker G.T., Houston J.B., Huang S.-M. (2001): Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm. Res., 18, 1071-1080.
6. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A. (2003): The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos., 31, 815-832.
7. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. (1951): Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
8. Rutten A.A.J.J.L., Falke H.E., Catsburg J.F., Topp R., Blaauboer B.J., Van Holsteijn I., Doorn L., Van Leeuwen F.X.R. (1987): Interlaboratory comparison of total cytochrome P-450 and protein determinations in rat liver microsomes. Reinvestigation of assay conditions. Arch. Toxicol., 61, 27-33.
9. Clarke S.E. (1998): In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167-1202.
10. Miners J.O., Smith K.J., Robson R.A., McManus M.E., Veronese M.E., Birkett D.J. (1988): Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol., 37, 1137-1144.
11. Kronbach T., Mathys D., Gut J., Catin T., Meyer U.A. (1987): High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem., 162, 24-32.
12. Sonderfan A.J., Arlotto M.P., Dutton D.R., McMillen S.K., Parkinson A. (1987): Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys., 255, 27-41.
13. Parker G.L., Orton T.C. (1980): Induction by oxyisobutyrates of hepatic and kidney microsomal cytochrome P-450 with specificity towards hydroxylation of fatty acids. In: Gustafsson J., Carlstedt-Duke J., Mode A., Rafter J. (eds). Biochemistry, Biophysics and Regulation of Cytochrome P-450. Amsterdam: Elsevier/North-Holland Biomedical Press, 373-377.
14. 14C-ciclesonide in hepatocytes from the mouse, rat, rabbit, dog and human. Submitted to Xenobiotica.
15. Clarke S.E., Jones B.C. (2002): Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In: Rodrigues A.D. (ed). Drug-Drug Interactions New York and Basel: Marcel Dekker, 55-88.
16. Nave R., Drollman A., Steinijans V.W., Zech K., Bethke T.D. (2005): Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int. J. Clin. Pharmacol. Ther., 43, 264-270.
17. LeBouef E., Grech-Bélanger O. (1987): Deacetylation of diltiazem by rat liver. Drug Metab. Dispos., 15, 122-126.
18. Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., Tsutsui M. (1996): Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
19. Mutch E., Nave R., Zech K., Williams F.M. (2003): Esterases involved in the hydrolysis of ciclesonide in human tissues. Eur. Respir. J., 22 [Suppl. 45], P1749.
20. Ong C.-E., Coulter, S., Birkett, D.J., Bhasker C.R., Miners, J.O. (2000): The xenobiotic inhibitor profile of cytochrome P4502C8. Br. J. Clin. Pharmacol., 50, 573-580.
21. Jönsson G., Ström A., Andersson P. (1995): Budesonide is metabolised by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos., 23, 137-142.
22. Chu V., Zeng Z., Pan J., Wei Y.-Y. V., Rao Z., Chen J., King S.P. (2004): In vitro assessment of cytochrome P450 metabolic drug-drug interaction potential of ciclesonide. Drug Metab. Rev., 36 [Suppl. 1], 276.